These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

535 related items for PubMed ID: 16804852

  • 1. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection.
    Ritmeijer K, Dejenie A, Assefa Y, Hundie TB, Mesure J, Boots G, den Boer M, Davidson RN.
    Clin Infect Dis; 2006 Aug 01; 43(3):357-64. PubMed ID: 16804852
    [Abstract] [Full Text] [Related]

  • 2. Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence.
    Ritmeijer K, ter Horst R, Chane S, Aderie EM, Piening T, Collin SM, Davidson RN.
    Clin Infect Dis; 2011 Dec 01; 53(12):e152-8. PubMed ID: 22016502
    [Abstract] [Full Text] [Related]

  • 3. Oral miltefosine for Indian visceral leishmaniasis.
    Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, Junge K, Bryceson A, Berman J.
    N Engl J Med; 2002 Nov 28; 347(22):1739-46. PubMed ID: 12456849
    [Abstract] [Full Text] [Related]

  • 4. Miltefosine for visceral leishmaniasis relapse treatment and secondary prophylaxis in HIV-infected patients.
    Marques N, Sá R, Coelho F, Oliveira J, Saraiva Da Cunha J, Meliço-Silvestre A.
    Scand J Infect Dis; 2008 Nov 28; 40(6-7):523-6. PubMed ID: 18584541
    [Abstract] [Full Text] [Related]

  • 5. High parasitological failure rate of visceral leishmaniasis to sodium stibogluconate among HIV co-infected adults in Ethiopia.
    Diro E, Lynen L, Mohammed R, Boelaert M, Hailu A, van Griensven J.
    PLoS Negl Trop Dis; 2014 May 28; 8(5):e2875. PubMed ID: 24854196
    [Abstract] [Full Text] [Related]

  • 6. Safety and effectiveness of meglumine antimoniate in the treatment of Ethiopian visceral leishmaniasis patients with and without HIV co-infection.
    Hailu W, Weldegebreal T, Hurissa Z, Tafes H, Omollo R, Yifru S, Balasegaram M, Hailu A.
    Trans R Soc Trop Med Hyg; 2010 Nov 28; 104(11):706-12. PubMed ID: 20870258
    [Abstract] [Full Text] [Related]

  • 7. Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome.
    ter Horst R, Collin SM, Ritmeijer K, Bogale A, Davidson RN.
    Clin Infect Dis; 2008 Jun 01; 46(11):1702-9. PubMed ID: 18419422
    [Abstract] [Full Text] [Related]

  • 8. Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar.
    Das VN, Ranjan A, Bimal S, Siddique NA, Pandey K, Kumar N, Verma N, Singh VP, Sinha PK, Bhattacharya SK.
    Natl Med J India; 2005 Jun 01; 18(3):131-3. PubMed ID: 16130613
    [Abstract] [Full Text] [Related]

  • 9. Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya.
    Moore E, O'Flaherty D, Heuvelmans H, Seaman J, Veeken H, de Wit S, Davidson RN.
    Bull World Health Organ; 2001 Jun 01; 79(5):388-93. PubMed ID: 11417033
    [Abstract] [Full Text] [Related]

  • 10. Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis.
    Sundar S, Jha TK, Sindermann H, Junge K, Bachmann P, Berman J.
    Pediatr Infect Dis J; 2003 May 01; 22(5):434-8. PubMed ID: 12792385
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India.
    Bhattacharya SK, Jha TK, Sundar S, Thakur CP, Engel J, Sindermann H, Junge K, Karbwang J, Bryceson AD, Berman JD.
    Clin Infect Dis; 2004 Jan 15; 38(2):217-21. PubMed ID: 14699453
    [Abstract] [Full Text] [Related]

  • 12. Successful treatment of post-kala-azar dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe.
    Rihl M, Stoll M, Ulbricht K, Bange FC, Schmidt RE.
    J Infect; 2006 Jul 15; 53(1):e25-7. PubMed ID: 16274744
    [Abstract] [Full Text] [Related]

  • 13. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine.
    Sundar S, Rai M, Chakravarty J, Agarwal D, Agrawal N, Vaillant M, Olliaro P, Murray HW.
    Clin Infect Dis; 2008 Oct 15; 47(8):1000-6. PubMed ID: 18781879
    [Abstract] [Full Text] [Related]

  • 14. Oral miltefosine for the treatment of Indian visceral leishmaniasis.
    Sundar S, Jha TK, Thakur CP, Bhattacharya SK, Rai M.
    Trans R Soc Trop Med Hyg; 2006 Dec 15; 100 Suppl 1():S26-33. PubMed ID: 16730038
    [Abstract] [Full Text] [Related]

  • 15. The initial effectiveness of liposomal amphotericin B (AmBisome) and miltefosine combination for treatment of visceral leishmaniasis in HIV co-infected patients in Ethiopia: A retrospective cohort study.
    Abongomera C, Diro E, de Lima Pereira A, Buyze J, Stille K, Ahmed F, van Griensven J, Ritmeijer K.
    PLoS Negl Trop Dis; 2018 May 15; 12(5):e0006527. PubMed ID: 29799869
    [Abstract] [Full Text] [Related]

  • 16. Treatment outcomes of visceral leishmaniasis in Ethiopia from 2001 to 2017: a systematic review and meta-analysis.
    Gebreyohannes EA, Bhagvathula AS, Abegaz TM, Seid MA.
    Infect Dis Poverty; 2018 Oct 19; 7(1):108. PubMed ID: 30340519
    [Abstract] [Full Text] [Related]

  • 17. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis.
    Jha TK, Sundar S, Thakur CP, Bachmann P, Karbwang J, Fischer C, Voss A, Berman J.
    N Engl J Med; 1999 Dec 09; 341(24):1795-800. PubMed ID: 10588964
    [Abstract] [Full Text] [Related]

  • 18. Intralesional sodium stibogluconate alone or its combination with either intramuscular sodium stibogluconate or oral ketoconazole in the treatment of localized cutaneous leishmaniasis: a comparative study.
    El-Sayed M, Anwar AE.
    J Eur Acad Dermatol Venereol; 2010 Mar 09; 24(3):335-40. PubMed ID: 19744259
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of thermotherapy to treat cutaneous leishmaniasis caused by Leishmania tropica in Kabul, Afghanistan: a randomized, controlled trial.
    Reithinger R, Mohsen M, Wahid M, Bismullah M, Quinnell RJ, Davies CR, Kolaczinski J, David JR.
    Clin Infect Dis; 2005 Apr 15; 40(8):1148-55. PubMed ID: 15791515
    [Abstract] [Full Text] [Related]

  • 20. Long term failure of miltefosine in the treatment of refractory visceral leishmaniasis in AIDS patients.
    Troya J, Casquero A, Refoyo E, Fernández-Guerrero ML, Górgolas M.
    Scand J Infect Dis; 2008 Apr 15; 40(1):78-80. PubMed ID: 17852921
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.